Company Active LTD

Company profile

C-Major Limited

UK company 05563638, incorporated on 14 September 2005.

Home - C Major Medical

C-Major Limited is a UK company with status active founded in 2005 based in South East England.

Company number
05563638
Incorporated
14 Sep 2005
Companies House status
Active

Company identity

Founded / incorporated
14 September 2005

Company number 05563638

Verify at Companies House
Legal name
C-MAJOR LIMITED
Company type
LTD
Region
South East England
Registered address
Unknown
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

2 events
30 Jul
2026

Accounts With Accounts Type Micro Entity

Accounts Analysed

AA | Transaction MzUzNTk5MDIxOWFkaXF6a2N4

Published 30 Jul 2026 08:36

14 Sep
2005

Incorporated

Inception

Company registered at Companies House

Public funding

4 awards
First funded
2012
Funded years
2012, 2018, 2019, 2020
Age at first award
6 years

Projects

2020 Feasibility Studies Lead participant

Auto-retractable safety syringe for aspiration and injection - User Trials

1 Jun 2020 to 31 Mar 2021

Awarded
£84,500
Total cost £84,500

no public description

2019 Feasibility Studies Lead participant

Auto-retractable safety syringe for aspiration and injection

1 Jul 2019 to 30 Jun 2021

Awarded
£485,042
Total cost £692,917

Occupational exposures of healthcare personnel to bloodborne pathogens are frequent events in hospitals / medical settings. A needle-stick injury occurs when a syringe that has been in a patient accidentally punctures another person's skin. They have the potential to transmit blood-borne infections, including hepatitis B virus, hepatitis C virus and human...

2018 Feasibility Studies Lead participant

CODA- a device to allow the safe transfer of fluids from the DUET, a retractable safety syringe

1 Jan 2018 to 30 Sep 2018

Awarded
£104,721
Total cost £149,601

A needle-stick injury (NSI) occurs when a syringe that has been in a patient, accidentally punctures another person’s skin posing risk of bloodborne viruses (e.g. Hepatitis B and C and HIV). Cost of NSIs to the NHS is £500m and $2bn in the US. The “safe syringe” market has grown quickly to >$3bn but NSIs are not falling significantly and USA data shows mo...

2012 GRD Proof of Concept Lead participant

Project C-Major

1 Apr 2012 to 31 Mar 2013

Awarded
£100,000
Total cost £183,244

What is the problem? 40bn hypodermic devices are sold annually. After use and before safe disposal millions of people throughout the world suffer needle-stick injuries (NI) from used devices. The main risk posed by NI’s is exposure to blood-borne viruses. There are numerous offerings of “safe” devices to address this problem and legislation is in place in...

Product types

Feasibility Studies GRD Proof of Concept